Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain.

Wheeler JM, McMillan P, Strovas TJ, Liachko NF, Amlie-Wolf A, Kow RL, Klein RL, Szot P, Robinson L, Guthrie C, Saxton A, Kanaan NM, Raskind M, Peskind E, Trojanowski JQ, Lee VMY, Wang LS, Keene CD, Bird T, Schellenberg GD, Kraemer B.

Sci Transl Med. 2019 Dec 18;11(523). pii: eaao6545. doi: 10.1126/scitranslmed.aao6545.

PMID:
31852801
2.

Genome wide analysis reveals heparan sulfate epimerase modulates TDP-43 proteinopathy.

Liachko NF, Saxton AD, McMillan PJ, Strovas TJ, Keene CD, Bird TD, Kraemer BC.

PLoS Genet. 2019 Dec 13;15(12):e1008526. doi: 10.1371/journal.pgen.1008526. eCollection 2019 Dec.

3.

Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau.

Waldherr SM, Strovas TJ, Vadset TA, Liachko NF, Kraemer BC.

Nat Commun. 2019 Sep 30;10(1):4443. doi: 10.1038/s41467-019-12070-3.

4.

Resistance and resilience to Alzheimer's disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort.

Latimer CS, Burke BT, Liachko NF, Currey HN, Kilgore MD, Gibbons LE, Henriksen J, Darvas M, Domoto-Reilly K, Jayadev S, Grabowski TJ, Crane PK, Larson EB, Kraemer BC, Bird TD, Keene CD.

Acta Neuropathol Commun. 2019 Jun 7;7(1):91. doi: 10.1186/s40478-019-0743-1. Erratum in: Acta Neuropathol Commun. 2019 Aug 14;7(1):131.

5.

Tau tubulin kinases in proteinopathy.

Taylor LM, McMillan PJ, Kraemer BC, Liachko NF.

FEBS J. 2019 Jul;286(13):2434-2446. doi: 10.1111/febs.14866. Epub 2019 May 22. Review.

PMID:
31034749
6.

Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects.

Mitra J, Guerrero EN, Hegde PM, Liachko NF, Wang H, Vasquez V, Gao J, Pandey A, Taylor JP, Kraemer BC, Wu P, Boldogh I, Garruto RM, Mitra S, Rao KS, Hegde ML.

Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4696-4705. doi: 10.1073/pnas.1818415116. Epub 2019 Feb 15.

7.

Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration.

Taylor LM, McMillan PJ, Liachko NF, Strovas TJ, Ghetti B, Bird TD, Keene CD, Kraemer BC.

Mol Neurodegener. 2018 Feb 6;13(1):7. doi: 10.1186/s13024-018-0237-9.

8.

Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of Clinical Repurposing.

Weeks JC, Roberts WM, Leasure C, Suzuki BM, Robinson KJ, Currey H, Wangchuk P, Eichenberger RM, Saxton AD, Bird TD, Kraemer BC, Loukas A, Hawdon JM, Caffrey CR, Liachko NF.

Sci Rep. 2018 Jan 17;8(1):975. doi: 10.1038/s41598-017-18457-w.

9.

TDP-43/FUS in motor neuron disease: Complexity and challenges.

Guerrero EN, Wang H, Mitra J, Hegde PM, Stowell SE, Liachko NF, Kraemer BC, Garruto RM, Rao KS, Hegde ML.

Prog Neurobiol. 2016 Oct - Nov;145-146:78-97. doi: 10.1016/j.pneurobio.2016.09.004. Epub 2016 Sep 28. Review.

10.

The phosphatase calcineurin regulates pathological TDP-43 phosphorylation.

Liachko NF, Saxton AD, McMillan PJ, Strovas TJ, Currey HN, Taylor LM, Wheeler JM, Oblak AL, Ghetti B, Montine TJ, Keene CD, Raskind MA, Bird TD, Kraemer BC.

Acta Neuropathol. 2016 Oct;132(4):545-61. doi: 10.1007/s00401-016-1600-y. Epub 2016 Jul 29.

11.

Loss of RAD-23 Protects Against Models of Motor Neuron Disease by Enhancing Mutant Protein Clearance.

Jablonski AM, Lamitina T, Liachko NF, Sabatella M, Lu J, Zhang L, Ostrow LW, Gupta P, Wu CY, Doshi S, Mojsilovic-Petrovic J, Lans H, Wang J, Kraemer B, Kalb RG.

J Neurosci. 2015 Oct 21;35(42):14286-306. doi: 10.1523/JNEUROSCI.0642-15.2015.

12.

The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.

Liachko NF, McMillan PJ, Strovas TJ, Loomis E, Greenup L, Murrell JR, Ghetti B, Raskind MA, Montine TJ, Bird TD, Leverenz JB, Kraemer BC.

PLoS Genet. 2014 Dec 4;10(12):e1004803. doi: 10.1371/journal.pgen.1004803. eCollection 2014 Dec.

13.

Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.

Salado IG, Redondo M, Bello ML, Perez C, Liachko NF, Kraemer BC, Miguel L, Lecourtois M, Gil C, Martinez A, Perez DI.

J Med Chem. 2014 Mar 27;57(6):2755-72. doi: 10.1021/jm500065f. Epub 2014 Mar 12.

14.

CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.

Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JB, Kraemer BC.

Ann Neurol. 2013 Jul;74(1):39-52. doi: 10.1002/ana.23870. Epub 2013 Jul 8.

15.

Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity.

McCormick AV, Wheeler JM, Guthrie CR, Liachko NF, Kraemer BC.

Biol Psychiatry. 2013 Mar 1;73(5):464-71. doi: 10.1016/j.biopsych.2012.08.027. Epub 2012 Nov 7.

16.

Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy.

Liachko NF, Guthrie CR, Kraemer BC.

J Neurosci. 2010 Dec 1;30(48):16208-19. doi: 10.1523/JNEUROSCI.2911-10.2010.

Supplemental Content

Loading ...
Support Center